Broader Options for Experimental Clinical Research in Melanoma - Time for Adaptive Platform Trials?

Does treatment order matter for metastatic melanoma? The long-term results of the phase II SECOMBIT trial, now published in NEJM Evidence, surely suggest so.1 The SECOMBIT trial randomly assigned 206 patients with B-type Raf kinase (BRAF)^V600-mutated metastatic melanoma into equal treatment groups: the first treatment group started with dual targeted therapy (encorafenib plus binimetinib), switching to immunotherapy (ipilimumab plus nivolumab) after progressive disease was observed; the second reversed that sequence; and the third prepended an induction phase of targeted therapy to the second group's treatment strategy (an addition that might help those whose disease progresses too fast for immunotherapy). [ABSTRACT FROM AUTHOR]